Inclisiran for Patients with Advanced Chronic Kidney Disease (Stages G4–G5)

Overview

Inclisiran significantly reduces LDL-C levels in patients with advanced chronic kidney disease (CKD) stages G4–G5, demonstrating a mean reduction of 65.6% at one year.

Background

Advanced CKD is associated with a high cardiovascular risk, making lipid control crucial yet challenging due to reduced statin efficacy and intolerance. Inclisiran, a novel siRNA therapy targeting PCSK9, has shown promise in lowering LDL-C levels, but data in patients with severe renal impairment are limited. This study aims to provide real-world evidence on the efficacy and safety of inclisiran in this high-risk population.

Data Highlights

Key Findings

• Inclisiran reduced LDL-C from 131.6 mg/dl to 46.1 mg/dl over one year.
• 80% of patients achieved LDL-C levels < 70 mg/dl.
• 60% of patients achieved LDL-C levels < 55 mg/dl.
• Renal function remained stable with eGFR values before and after treatment.
• A 27.4% reduction in median albuminuria was observed; however, this finding should not be attributed to inclisiran.

Clinical Implications

Inclisiran may be a viable option for managing elevated LDL-C in patients with advanced CKD who are statin intolerant or have not achieved lipid targets with conventional therapies. The favorable safety profile and sustained LDL-C reduction suggest its potential role in this high-risk population.

Conclusion

Inclisiran demonstrates significant LDL-C reduction in patients with advanced CKD.

Related Resources & Content

1. KDIGO, KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 2024 -- https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf?utm_source=openai
2. European Journal of Preventive Cardiology, Efficacy and safety of inclisiran based on background lipid-lowering treatment, 2023 -- https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwaf214/8115346
3. Clinical Research in Cardiology, Variability in LDL-Cholesterol Reduction Following Inclisiran Treatment in a Multicenter Study Across Germany, 2023 -- https://link.springer.com/article/10.1007/s00392-023-02247-8
4. European Journal of Preventive Cardiology, Forecasting the Effectiveness of Inclisiran in Individuals with Established Atherosclerotic Cardiovascular Disease: Insights from the SIRIUS In-Silico Model of Cardiovascular Outcomes, 2023 -- https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwaf783/8405449
5. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies, 2019 -- https://pubmed.ncbi.nlm.nih.gov/31630870/?utm_source=openai
6. European Journal of Preventive Cardiology — Efficacy and safety of inclisiran based on background lipid-lowering treatment
7. Clinical Research in Cardiology — Variability in LDL-Cholesterol Reduction Following Inclisiran Treatment in a Multicenter Study Across Germany
8. European Journal of Preventive Cardiology — Forecasting the Effectiveness of Inclisiran in Individuals with Established Atherosclerotic Cardiovascular Disease: Insights from the SIRIUS In-Silico Model of Cardiovascular Outcomes
9. Clinical Research in Cardiology — Patterns of Treatment and Achievement of Low-Density Lipoprotein Cholesterol (LDL-C) Targets in Patients on High- or Moderate-Intensity Statin Therapy
10. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
11. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies - PubMed
12. Clinical Review - Inclisiran (Leqvio) - NCBI Bookshelf